Verlinden L - Search Results

1

PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D.

Vanoirbeek E, Eelen G, Verlinden L, Carmeliet G, Mathieu C, Bouillon R, O'Connor R, Xiao G, Verstuyf A. Vanoirbeek E, et al. Among authors: verlinden l. Oncogene. 2014 Apr 10;33(15):1904-11. doi: 10.1038/onc.2013.123. Epub 2013 Apr 15. Oncogene. 2014. PMID: 23584482

2

Differentiation induction of human leukemia cells (HL60) by a combination of 1,25-dihydroxyvitamin D3 and retinoic acid (all trans or 9-cis).

Verstuyf A, Mathieu C, Verlinden L, Waer M, Tan BK, Bouillon R. Verstuyf A, et al. Among authors: verlinden l. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):431-41. doi: 10.1016/0960-0760(95)00089-i. J Steroid Biochem Mol Biol. 1995. PMID: 7626492

3

Non-hypercalcemic pharmacological aspects of vitamin D analogs.

Bouillon R, Verstuyf A, Verlinden L, Allewaert K, Branisteanu D, Mathieu C, van Baelen H. Bouillon R, et al. Among authors: verlinden l. Biochem Pharmacol. 1995 Aug 25;50(5):577-83. doi: 10.1016/0006-2952(95)00121-f. Biochem Pharmacol. 1995. PMID: 7669059 Review. No abstract available.

4

Differentiation induction of HL60 cells by 1,25(OH)2D3, all trans retinoic acid, rTGF-beta2 and their combinations.

Verlinden L, Verstuyf A, Mathieu C, Tan BK, Bouillon R. Verlinden L, et al. J Steroid Biochem Mol Biol. 1997 Jan;60(1-2):87-97. doi: 10.1016/s0960-0760(96)00174-4. J Steroid Biochem Mol Biol. 1997. PMID: 9182862

5

The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings.

Verstuyf A, Verlinden L, Van Baelen H, Sabbe K, D'Hallewyn C, De Clercq P, Vandewalle M, Bouillon R. Verstuyf A, et al. Among authors: verlinden l. J Bone Miner Res. 1998 Apr;13(4):549-58. doi: 10.1359/jbmr.1998.13.4.549. J Bone Miner Res. 1998. PMID: 9556055 Free article.

6

Recent developments in the use of vitamin D analogues.

Verstuyf A, Segaert S, Verlinden L, Casteels K, Bouillon R, Mathieu C. Verstuyf A, et al. Among authors: verlinden l. Curr Opin Nephrol Hypertens. 1998 Jul;7(4):397-403. doi: 10.1097/00041552-199807000-00008. Curr Opin Nephrol Hypertens. 1998. PMID: 9690038 Review.

7

Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells.

Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R. Verlinden L, et al. Mol Cell Endocrinol. 1998 Jul 25;142(1-2):57-65. doi: 10.1016/s0303-7207(98)00117-8. Mol Cell Endocrinol. 1998. PMID: 9783903

8

Nonclassical effects of 1alpha,25-dihydroxyvitamin D(3) and its analogs.

Verstuyf A, Verlinden L, Segaert S, Van Etten E, Mathieu C, Bouillon R. Verstuyf A, et al. Among authors: verlinden l. Miner Electrolyte Metab. 1999 Jul-Dec;25(4-6):345-8. doi: 10.1159/000057472. Miner Electrolyte Metab. 1999. PMID: 10681664 Review.

9

Biological activity of CD-ring modified 1alpha,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues.

Verstuyf A, Verlinden L, van Etten E, Shi L, Wu Y, D'Halleweyn C, Van Haver D, Zhu GD, Chen YJ, Zhou X, Haussler MR, De Clercq P, Vandewalle M, Van Baelen H, Mathieu C, Bouillon R. Verstuyf A, et al. Among authors: verlinden l. J Bone Miner Res. 2000 Feb;15(2):237-52. doi: 10.1359/jbmr.2000.15.2.237. J Bone Miner Res. 2000. PMID: 10703925 Free article.

10

Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo.

Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao XY, De Clercq P, Vandewalle M, Bouillon R. Verlinden L, et al. Cancer Res. 2000 May 15;60(10):2673-9. Cancer Res. 2000. PMID: 10825140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page